The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes

OBJECTIVE Exenatide improves postprandial glycemic excursions in type 2 diabetes. Exenatide could benefit type 1 diabetes as well. We aimed to determine an effective and safe glucose-lowering adjuvant exenatide dose in adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS Eight subjects completed a three-part double-blinded randomized controlled study of premeal exenatide. Two doses of exenatide (1.25 and 2.5 μg) were compared with insulin monotherapy. Prandial insulin dose was reduced by 20%. Gastric emptying and hormones were analyzed for 300 min postmeal. RESULTS Treatment with both doses of exenatide versus insulin monotherapy significantly reduced glucose excursions over 300 min (P < 0.0001). Exenatide administration failed to suppress glucagon but delayed gastric emptying (P < 0.004). CONCLUSIONS Adjunctive exenatide therapy reduces postprandial hyperglycemia in adolescents with type 1 diabetes. This reduction in glucose excursion occurs despite reduction in insulin dose. We suggest that exenatide has therapeutic potential as adjunctive therapy in type 1 diabetes.

[1]  J. Holst,et al.  GLP‐1: physiological effects and potential therapeutic applications , 2008, Diabetes, obesity & metabolism.

[2]  M. Haymond,et al.  The Role of Prandial Pramlintide in the Treatment of Adolescents With Type 1 Diabetes , 2007, Pediatric Research.

[3]  M. Fisher,et al.  Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) , 2007 .

[4]  G. Steil,et al.  Feasibility of Automating Insulin Delivery for the Treatment of Type 1 Diabetes , 2006, Diabetes.

[5]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[6]  D. Drucker.  Enhancing the action of incretin hormones: a new whey forward? , 2006, Endocrinology.

[7]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[8]  M. Haymond,et al.  The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. , 2005, Diabetes.

[9]  T. McDonald,et al.  Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[10]  A. Young,et al.  Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes , 2004, Regulatory Peptides.

[11]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[12]  P. Zabel,et al.  Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM , 1995, Diabetes.

[13]  D. Rogers,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus , 1994 .

[14]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[15]  Weight Gain Associated With Intensive Therapy in the Diabetes Control and Complications Trial , 1988, Diabetes Care.

[16]  C. Weyer,et al.  Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone. , 2002, Diabetes technology & therapeutics.